Psoriasis

The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.

Latest News

Medicines on shelf - Prasanth - stock.adobe.com.jpg
Rising Costs of Biologics for Plaque Psoriasis Highlight Savings Potential

April 24th 2025

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one study.

Plaque psoriasis | Image credit: Milan Lipowski - stock.adobe.com
Icotrokinra Shows Clear Skin in 75% of Adolescents With Plaque Psoriasis in Phase 3 Trial

April 10th 2025

Psoriasis oral treatment | Image credit: Pawel - stock.adobe.com
Women Have Lower Drug Survival With Biologics for Psoriasis, Including IL-17 and IL-23 Inhibitors

April 7th 2025

Psoriasis treatment concept | Sviatlana - stock.adobe.com
Tildrakizumab Effective Up to Nearly 3 Years Regardless of BSA Affected, Obesity

April 1st 2025

Bimekizumab | Image credit: luchschenF - stock.adobe.com
Bimekizumab Reduces Inflammation, Cardiovascular Risk

March 21st 2025

A Personalized Approach to Disease Management in Psoriasis

A panel of experts discuss their personalized approaches to treating patients with psoriasis and comorbidities such as metabolic syndrome.

Ryan Haumschild, PharmD, MS, MBA, Bhavesh Shah, PharmD, Mark Lebwohl, MD, and Robert Groves, MD.
Continuing Medical Education
View All
April 25th 2025

Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care

1.5 Credits / Dermatology, Immunology
April 25th 2025

Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care

1.5 Credits / Dermatology

More News

Monitoring for Psoriasis Comorbidities and Associated Complications
October 22nd 2019

Monitoring for Psoriasis Comorbidities and Associated Complications

Prevalence and Burden of Psoriasis and Metabolic Syndrome
October 22nd 2019

Prevalence and Burden of Psoriasis and Metabolic Syndrome

Association Between Psoriasis, PsA and Metabolic Syndrome
October 22nd 2019

Association Between Psoriasis, PsA and Metabolic Syndrome

Definition, Diagnosis, and Progression of Psoriasis
October 22nd 2019

Definition, Diagnosis, and Progression of Psoriasis

Tildrakizumab Shows Benefit for Patients With Psoriasis With Metabolic Syndrome
October 21st 2019

Tildrakizumab Shows Benefit for Patients With Psoriasis With Metabolic Syndrome

Allison Inserro
A recent study illustrated the benefits of tildrakizumab for patients with psoriasis with comorbid metabolic syndrome.
Researchers Describe Concomitant Interstitial Lung Disease With Psoriasis
October 19th 2019

Researchers Describe Concomitant Interstitial Lung Disease With Psoriasis

AJMC Staff
A recent case series examined clinical and radiographic characteristics of patients with concomitant psoriasis and interstitial lung disease (ILD).
Severe Psoriasis Linked to Higher Risk of Death From Liver, Esophageal, Pancreatic Cancers
October 16th 2019

Severe Psoriasis Linked to Higher Risk of Death From Liver, Esophageal, Pancreatic Cancers

Allison Inserro
Patients with severe psoriasis have an increased risk of dying from liver, esophageal, and pancreatic cancers, and people with psoriasis have an overall increased risk of a variety of other cancers, according to a meta-analysis and review published Wednesday in JAMA Dermatology.
Dr Steven R. Feldman on the Effect of Metabolic Syndrome on Treatments for Psoriasis
October 12th 2019

Dr Steven R. Feldman on the Effect of Metabolic Syndrome on Treatments for Psoriasis

Steven R. Feldman, MD, PhD, professor of dermatology, Wake Forest School of Medicine, discusses how some drugs for psoriasis are less effective in the presence of metabolic syndrome.
Study Links Severity of Psoriasis, Nonalcoholic Fatty Liver Disease
October 10th 2019

Study Links Severity of Psoriasis, Nonalcoholic Fatty Liver Disease

Mary Caffrey
Previous work has linked psoriasis and nonalcoholic fatty liver disease, but this is one of the first studies to tie together the severity of the 2 conditions.
Dr Steven R. Feldman on Managing Psoriasis in Patients With Metabolic Syndrome
October 5th 2019

Dr Steven R. Feldman on Managing Psoriasis in Patients With Metabolic Syndrome

Steven R. Feldman, MD, PhD, professor of dermatology, Wake Forest School of Medicine, discusses the challenges clinicians face when managing psoriasis in patients who also have metabolic syndrome.
PASI Scores Can Indicate Who Will, Will Not Respond to Tildrakizumab for Psoriasis, Study Says
October 1st 2019

PASI Scores Can Indicate Who Will, Will Not Respond to Tildrakizumab for Psoriasis, Study Says

AJMC Staff
Knowing who may respond to tildrakizumab early on may help providers and patients decide whether to continue with treatment, the researchers said.
Site Logo
September 27th 2019

Poster Recap: Associations Among Opioid Use, Outpatient Visits, and Comorbidities in Patients With Moderate-to-Severe Psoriasis

Zhdanava M, Teeple A, Pilon D, Shak N, Fitzgerald T, Lefebvre P. Opioid healthcare resource use among privately insured moderate-to-severe psoriasis patients in the US. Poster presented at: ISPOR 2019 May 18-22, 2019 New Orleans, LA. ispor.org/heor-resources/presentations-database/presentation/intl2019-2217/92246.
Site Logo
September 27th 2019

Poster Recap: Comorbidities, Infections, and Treatments of Patients With Psoriasis

Peyerl FW, Varsos GV, Shen M, et al. Comorbidities, infections treatment patterns in psoriasis patients: a retrospective analysis of a large US electronic health record database. Poster presented at: ISPOR 2019 May 18-22, 2019 New Orleans, LA. ispor.org/heor-resources/presentations-database/presentation/intl2019-2217/91304.
Site Logo
September 27th 2019

Poster Recap: Biologics and Apremilast Adherence Patterns of Patients With Moderate to Severe Plaque Psoriasis Grouped by Metabolic Syndrome Status

Feldman SR, Zhang J, Martinez D, et al. Treatment patterns of biologics apremilast among patients with moderate to severe plaque psoriasis by metabolic syndrome status. Poster presented at: ISPOR 2019 May 18-22, 2019 New Orleans, LA. ispor.org/heor-resources/presentations-database/presentation/intl2019-1479/92502.
Site Logo
September 27th 2019

Poster Recap: Adherence Rates and Additional Treatment Patterns With Biologics and Apremilast for Moderate-to-Severe Plaque Psoriasis

Feldman SR, Zhang J, Zhao Y, et al. Apremilast treatment patterns in moderate-to-severe plaque psoriasis. Poster presented at: AMCP Managed Care & Specialty Pharmacy Annual Meeting March 25-28, 2019 San Diego, CA.
No Association Between Biologics to Treat Psoriasis and Psychiatric Illness
September 26th 2019

No Association Between Biologics to Treat Psoriasis and Psychiatric Illness

Laura Joszt, MA
Patients with psoriasis who were treated with biologics were less likely to develop psychiatric illnesses compared with patients not treated with biologics; however, the researchers did note treatment selection may have influenced the findings.
Early Levels of Ustekinumab May Predict Longer-term Response in Patients With Psoriasis
September 21st 2019

Early Levels of Ustekinumab May Predict Longer-term Response in Patients With Psoriasis

Laura Joszt, MA
Measurement of drug levels early in treatment with ustekinumab for patients with psoriasis may be able to successfully predict patient response and, therefore, direct a treatment strategy.
Researchers Examine Metabolic Syndrome Links to Inflammatory Skin Disorder Lichen Planus
September 20th 2019

Researchers Examine Metabolic Syndrome Links to Inflammatory Skin Disorder Lichen Planus

AJMC Staff
Psoriasis is known to be linked with metabolic syndrome, which is triggered by chronic inflammation and fosters obesity and dyslipidemia. A recent study looked at another chronic inflammatory skin disease, lichen planus, to better understand any associations with metabolic syndrome.
Case Report Describes Patient With Psoriasis Who Developed IBD After Secukinumab
September 11th 2019

Case Report Describes Patient With Psoriasis Who Developed IBD After Secukinumab

Allison Inserro
The discussion about whether existing inflammatory bowel disease (IBD) or new IBD can worsen after secukinumab therapy is not resolved, the researchers said.
Could Understanding HLA-C Lead to Precision Therapy in Psoriatic Arthritis?
September 9th 2019

Could Understanding HLA-C Lead to Precision Therapy in Psoriatic Arthritis?

Kelly Davio
Human leukocyte antigen c (HLA‐C), a protein encoded by the HLA-C gene, plays an important role in protecting against both cancer and viruses. At the same time, it has been implicated in autoimmune diseases, including rheumatic diseases, though the mechanism by which it contributes to the pathogenesis of these diseases is not yet clear.
More Research Needed About Link Between Psoriasis, Alcohol
September 5th 2019

More Research Needed About Link Between Psoriasis, Alcohol

Allison Inserro
Some patients may use alcohol to cope with the psychological and social aspect of psoriatic disease, but using alcohol may be associated with worse adherence to treatment.
Screen Patients With Psoriasis for Obstructive Sleep Apnea, Researchers Say
September 3rd 2019

Screen Patients With Psoriasis for Obstructive Sleep Apnea, Researchers Say

AJMC Staff
Patients with psoriasis should be opportunistically screened for obstructive sleep apnea, an independent risk factor for cardiovascular disease, said the authors of a recent study.
5 Things About Psoriasis and Its Complications
August 30th 2019

5 Things About Psoriasis and Its Complications

Allison Inserro
August is National Psoriasis Month, which aims to raise awareness about this chronic autoimmune disease affecting more than 8 million Americans. Here are 5 things to know about psoriasis and its complications.
Psoriasis Patient Group Seeks to Curb Step Therapy Use With State Legislation
August 30th 2019

Psoriasis Patient Group Seeks to Curb Step Therapy Use With State Legislation

Allison Inserro
The National Psoriasis Foundation is working to get laws to curb to step therapy practices at the state level.
Celgene Sells Psoriasis Drug Otezla to Amgen for $13.4 Billion
August 26th 2019

Celgene Sells Psoriasis Drug Otezla to Amgen for $13.4 Billion

Allison Inserro
The price for Otezla is higher than many analysts expected.
US Patients With Psoriasis Face 2-Fold Mortality Risk, Study Finds
August 22nd 2019

US Patients With Psoriasis Face 2-Fold Mortality Risk, Study Finds

Mary Caffrey
Findings appeared this month in the Journal of the American Academy of Dermatology.
Treating RA With Anti-TNF Agents Is Linked With a Higher Risk of Incident Psoriasis
August 19th 2019

Treating RA With Anti-TNF Agents Is Linked With a Higher Risk of Incident Psoriasis

Kelly Davio
Biologics have become the standard of care for rheumatoid arthritis (RA) that fails to respond adequately to conventional disease-modifying antirheumatic agents (DMARDs), and overall, these agents are safe and effective. However, an association between treatment with anti–tumor necrosis factor (anti-TNF) agents and new-onset psoriasis in patients with RA has been observed.
Researcher Excited About Future of Psoriasis Treatment
August 16th 2019

Researcher Excited About Future of Psoriasis Treatment

Allison Inserro
A psoriasis researcher discusses a new class of psoriasis treatments.
Obesity, Insulin Resistance Are Linked With Advanced Liver Fibrosis in Patients With Psoriasis
August 12th 2019

Obesity, Insulin Resistance Are Linked With Advanced Liver Fibrosis in Patients With Psoriasis

Kelly Davio
“Our data suggest that people with central obesity, insulin resistance, and active psoriasis are the most at risk for liver fibrosis,” wrote the authors, and “if use of methotrexate is a risk factor, it is not the only risk factor and for most patients it is unlikely to be the most important risk factor.”
Subclinical Atherosclerosis Seen in Patients With Psoriatic Arthritis
August 9th 2019

Subclinical Atherosclerosis Seen in Patients With Psoriatic Arthritis

AJMC Staff
A recent review of biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis (PsA) showed more severe atherosclerotic disease compared with patients who have only psoriasis.
<1
...
9101112131415>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo